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Abstract
The replacement of functional pancreatic β-cells is seen as an attractive potential
therapy for diabetes, because diabetes results from an inadequate β-cell mass.
Inducing replication of the remaining β-cells and new islet formation from
progenitors within the pancreas (neogenesis) are the most direct ways to increase
the β-cell mass. Stimulation of both replication and neogenesis have been
reported in rodents, but their clinical significance must still be shown. Because
human islet transplantation is limited by the scarcity of donors and graft failure
within a few years, efforts have recently concentrated on the use of stem cells
to replace the deficient β-cells. Currently, embryonic stem cells and induced
pluripotent stem cells achieve high levels of β-cell differentiation, but their clinical
use is still hampered by ethical issues and/or the risk of developing tumors after
transplantation. Pancreatic epithelial cells (duct, acinar, or α-cells) represent an
appealing alterna...
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ABSTRACT
The replacement of functional pancreatic -cells is seen as an attractive potential therapy for dia-
betes, because diabetes results from an inadequate-cell mass. Inducing replication of the remain-
ing-cells and new islet formation from progenitors within the pancreas (neogenesis) are the most
direct ways to increase the -cell mass. Stimulation of both replication and neogenesis have been
reported in rodents, but their clinical significance must still be shown. Because human islet trans-
plantation is limited by the scarcity of donors and graft failure within a few years, efforts have
recently concentrated on the use of stem cells to replace the deficient-cells. Currently, embryonic
stem cells and induced pluripotent stem cells achieve high levels of -cell differentiation, but their
clinical use is still hampered by ethical issues and/or the risk of developing tumors after transplan-
tation. Pancreatic epithelial cells (duct, acinar, or-cells) represent an appealing alternative to stem
cells because they demonstrate -cell differentiation capacities. Yet translation of such capacity to
human cells after significant in vitro expansionhas yet to be achieved. Besides providing new-cells,
cell therapy also has to address the question on how to protect the transplanted cells from destruc-
tion by the immune system via either allo- or autoimmunity. Encouraging developments have been
made in encapsulation and immunomodulation techniques, but many challenges still remain.
Herein,we discuss recent advances in the search for-cell replacement therapies, current strategies
for circumventing the immune system, and mandatory steps for new techniques to be translated
from bench to clinics. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:150–159
INTRODUCTION
Diabetes results from an inadequate mass of func-
tional-cells. In type 1diabetes (T1D), the immune
system attacks and destroys the -cells by mecha-
nisms still incompletely understood [1]. Type 2 dia-
betes (T2D) accounts for 95% of diabetes cases
worldwideand is associatedwithobesity leading to
insulin resistance and -cell dysfunction. Exoge-
nous insulin or oral agents canprovide tight control
of the disease, but only the replacement of -cells
allows physiological control of glycemia. Human is-
let transplantation is successful in restoring normal
glycemia but is limited by the need for toxic immu-
nosuppressive drugs, the scarcity of donors, and
graft failure usually within a few years [2]. Alterna-
tive ways for replacing-cells are needed andmay
theoretically be obtained by (a) replication of re-
maining -cells, (b) neogenesis, or the differentia-
tion of new islet cells from pancreatic progenitors
or stem cells, and (c) transplantation of -cells de-
rived from stem or somatic precursor cells. These
areas of research, still being mostly experimental,
will be addressed in this review.
Evidence of In Vivo Regeneration Capacity
of -Cells
Much enthusiasm about regenerating pancreatic
-cells in situ has been driven by evidence of the
impressive proliferation capacity of postnatal ro-
dent -cells in situations of increased metabolic
demand [3]. For example, in the mouse, pre-ex-
isting -cells were shown to be responsible for
the pancreas regeneration that occurs after 70%
pancreatectomy, in a seminal work by Melton
and coworkers [4]. In the human, normal expan-
sion of the -cell mass occurs during the neona-
tal period but fades early in childhood [5]. -Cell
regeneration has been suggested by the obser-
vation of residual -cells in T1D patients after
onset [6] or even many years after diagnosis [7–
9]. Whether this represents a replication capac-
ity, neogenesis, or resistance to apoptosis is un-
known. Adult -cells have some capacity to
expand with obesity [10, 11] whereas -cell rep-
lication is usually negligible when analyzed at au-
topsy [10, 12, 13]. However, an interesting equiv-
alent of the “honeymoon period” has been
described in T1D patients during pregnancy with
measurable C-peptide levels and transient re-
duction of the insulin requirements [14]. Replica-
tion was initially suggested as the mechanism of
this phenomenon [15], but a recent autopsy
study on pancreases during or after pregnancy
suggested neogenesis by showing increased rel-
ative volume of -cells, increased proportion of
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small islets, and increased number of insulin cells in the ducts
but no change in -cell replication, cell size, or apoptosis fre-
quency [16]. Thus, the question remains open as to whether
-cell regeneration could be exploited for therapy.
Neogenesis has recently been a source of intense debate,
with many lineage tracing studies in mice showing contradictory
results [17]. Controversy reached its climax when two recent
reports obtained distinctly different results using similar tracing
methods for Sox9-expressing populations [18, 19]. Kopp et al.
described derivation of non--endocrine cells from the ducts in
early postnatal life but no endocrine or acinar cell neogenesis in
adult mice either physiologically or after pancreatic duct ligation
(PDL) [18]. However, Furuyama et al. obtained massive X-gal
staining of acinar cells 8weeks after tamoxifen pulseswere given
during the postnatal period in Sox9IRESCreERT2; Rosa26R mice
[19]. They also showed that duct cells accounted for amere 1%of
pancreatic endocrine cells at 8 weeks when tracing was initiated
on the first day of life. These results clearly underline technical
limitations of current lineage tracing approaches.
Neogenesis from ducts is influenced by the type and extent
of pancreatic injury. This was highlighted in a recent study show-
ing different regeneration depending on the affected cell type
and the extent of diphtheria toxin-induced apoptosis [20].When
both acinar and islet cells were massively killed by diphtheria
toxin expressed under the Pdx1 promoter, duct cells gave rise to
both acinar and endocrine cells, recovery of 60% of the -cell
mass, and reversal of hyperglycemia, but when only acinar cells
were killed by elastase-driven toxin, duct cells only gave rise to
new acinar cells. Also, neogenesis from the ducts seems to hap-
pen by recapitulating pancreatic embryonic development as
highlighted using a pancreatic duct ligation model in the mouse
[21] and partial pancreatectomy in the rat [22, 23].
In the human pancreas, indirect evidence of neogenesis has
been provided by showing cells coexpressing cytokeratin and
insulin [24]. Many studies have demonstrated the presence of
cells containing insulin within the ducts, either at autopsy [5] or
in biopsy from organ donors [24, 25]. Currently, the general con-
cept is that, after birth, neogenesis from ducts occurs mostly in
the neonatal period and, as shown in rodents, can be stimulated
in the regeneration following injury [17].
Stimulation of In Vivo Generation of New -Cells
In rodents, growth factors such as betacellulin [26] or combina-
tions of glucagon-like peptide (GLP)-1/gastrin [27] or epidermal
growth factor/gastrin [28, 29] have shown a potential for in-
creasing -cell mass and reversing diabetes. Data from rodents
showed that these factors stimulate -cell replication and neo-
genesis, but whether this happens in humans is unknown [2].
Islet neogenesis associated protein-pentadecapeptide (INGAP-
PP) generated interest after the report of its potential for stimu-
lating neogenesis and reversing diabetes in streptozotocin (STZ)-
treated mice [30]. However, INGAP-PP has met with equivocal
results when studied in humans, with only isolated parameters
being modestly improved (arginine-stimulated C-peptide secre-
tion in the T1D trial, HbA1C levels in the T2D trial) [31, 32]. The
therapeutic potential of such combinations or single agents in
humans has not been explored in enough detail to draw firm
conclusions.
Incretin therapy or GLP-1 receptor agonism has been consid-
ered to have potential for diabetes therapy after proof-of-con-
cept studieswere performed in T2Dpatientswith administration
of GLP-1 [33, 34]. Because of its short biological half-life, long-
acting analogues (namely, exenatide and liraglutide) and inhibi-
tors of the degrading enzyme DPPIV were developed that are
now widely used for treatment of T2D [35]. These agents are
likely to provide benefit for T2D patients through stimulation of
insulin secretion (incretin effect), inhibition of glucagon release,
delay of gastric emptying, and decrease of food intake. However,
although GLP-1 receptor agonism has been shown to increase
-cell mass in rodents [36, 37], long-term data have yet to pro-
vide evidence for such increase in T2D patients [38].
-Cell Replacement Therapy
(A) What Kind of Cells?
Embryonic Stem Cells. Embryonic stem cells (ESCs) have ad-
vantages over other potential sources because they are now
readily available, are highly expandable, and can be differenti-
ated to -cells [39]. Many studies have demonstrated the deri-
vation of Pdx1 or endocrine cells from ESCs, and some groups
generated insulin or C-peptide-secreting cells [40–42]. Using a
stepwise differentiation protocol mimicking pancreatic embry-
onic development, a team from Novocell (now Viacyte) drove
ESCs toward an endocrine phenotype in vitro and obtained up to
12% insulin cells [43]. When early pancreatic progenitors were
transplanted into diabetic SCID mice, over time these cells be-
came glucose-responsive and secreted large amounts of insulin,
comparable to amounts released from human islets, leading to
near normalization of blood glucose levels in the transplanted
animals [44].
Improvements of current differentiation procedures are still
mandatory to ensure their reproducibility. High-throughput
screening of small molecules appears to be an attractive ap-
proach to identify new compounds promoting differentiation
while being “clinical-friendly” [45, 46]. Additionally, three-di-
mensional (3D) organization of cell populations might foster
-cell differentiation [47], and studies are needed to evaluate at
which state of differentiation cellswould benefit fromcell-to-cell
interactions and which culture system (suspension culture, gels,
scaffolds) would be most suitable for implementation to clinical
situations. Lack of oxygen in the core of large 3D structures is a
limitation, and a recent study used a size-controlled clustering
protocol to derive endocrine precursors from human ESCs [48].
Whether extracellular matrices would give permissive signals for
differentiation [49] and could be incorporated into a 3D struc-
ture without altering cross-talk between cells requires investiga-
tion.
In addition to ethical issues, clinical use of ESCs is still seri-
ously hampered by the risk of in vivo teratoma formation [44,
50]. This risk is mainly associated with the transplantation of
undifferentiated phenotypes, and efforts are now being con-
centrated on the selection of differentiated cells. Recent stud-
ies showed the possibility of sorting for ESC-derived endoder-
mal cells using cell surface markers (CD49eCD141CD238
[51], EpCAMSSEA1SSEA3 [52], or CD24 selection [53])
without detectable teratoma formation 160 days post-trans-
plantation. Investigations are now needed to determine how re-
liable the elimination of undifferentiated cells can be, as only a
few cells are necessary for tumorogenesis. Also, differentiated
cells may retain epigenetic traits of original cells, as has been
described after reprogramming to pluripotency [54, 55], after
epithelial-mesenchymal transition (EMT) of -cells [56], and af-
ter transdifferentiation of hepatocytes into neurons [57].
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Whether the differentiated products might revert to a less dif-
ferentiated and potentially dangerous state is unknown.
Induced Pluripotent Stem Cells. Induced pluripotent stem
cells (iPSCs) have the unique property of allowing the generation
of autologous cells that might be useful for therapy [58]. The
-cell differentiation potential of iPSCs has been shown in vitro
with demonstration of partial glucose-responsive C-peptide re-
lease [42, 59, 60]. Moreover, recent studies highlighted the po-
tential of mouse [61] and rhesus monkey [62] iPSCs to reverse
hyperglycemia after in vitro differentiation and transplantation
in diabetic mouse models.
Although huge efforts are invested in iPSC research, hurdles
concerning their clinical application are multiple: long, complex,
and costly in vitro procedures; low reprogramming efficiency;
risk of insertional mutagenesis and of permanent transgene ge-
nome integration; tumor formation; use of Klf4 and c-Myc onco-
genic factors; and the need for animal feeder cells [63]. Safety
issues have recently been raised because coding mutations [64]
or epigenetic anomalies [65] were observed after reprogram-
ming, and undefined limitations also exist as to how to induce
iPSC differentiation without generating large numbers of undif-
ferentiated cells.
The search for nonintegrative techniques has generated new
possibilities, such as the use of syntheticmodifiedmRNA for Klf4,
c-Myc, Oct4, and Sox2 (KMOS) that appears to be a safer and
more efficient strategy for reprogramming [66]. Another team
described the successful reprogramming of mouse and human
somatic cells using miR302/367 microRNAs, with a twofold-en-
hanced efficiency compared with the KMOS strategy [67]. Even
more efficient (100) and faster reprogramming was obtained
using nonintegrating episomal vectors on bonemarrow and cord
blood cells [68]. In parallel, the replacement of oncogenic factors
in reprogramming protocols is important for safety. Accordingly,
Yamanaka and coworkers recently reported the efficient gener-
ation of iPSCs by replacing c-Myc in the KMOS protocol by Glis1,
a GLI-like transcription factor [69]. Further work is needed to
confirm the reliability and safety of these techniques. With the
aim of moving the iPSC field closer to clinical application, an
intense effort is focused on the use of small molecules that may
improve reprogramming efficiency [70] and even avoid the use
of transcription factors [71].
Human Pancreatic Epithelial Cells. (1) Human Islets. Because
islet donors are scarce, exploitation of human-cells for therapy
could be obtained by expanding the cells in vitro. Because epi-
thelial cells have limited mitotic activity in vitro, an alternative
way of forcing their expansion could be via a phenotype shift.
Accordingly, human -cells were shown to be able to proliferate
in vitro after shifting toward amesenchymal phenotype through
EMT [72]. These mesenchymal-like cells appear to have been
directly derived from original -cells, as confirmed by lineage
tracing experiments [73, 74] with human cells; however, mouse
-cells were shown not to be able to undergo EMT [75–77].
Moreover, it has not been convincingly shown that these mes-
enchymal-like cells can be differentiated into bona fide -cells.
Islets, as well as the ducts, were recently shown to contain a
population of pancreas-derived multipotent precursor (PMP)
cells that are isolated under clonal conditions (at the rate of 2.6
sphere-producing colonies per 10,000 cells) and generate pan-
creatic and neural lineages in vitro [78]. PMPs derived from hu-
man islets were able to reverse diabetes in STZ-treated NOD-
SCID mice [79]. This might represent another alternative use of
islet preparations for treating diabetes.
(2) Duct Cells. Several studies showed the potential for differ-
entiation of cells derived from the islet-depleted exocrine tissue
[78, 80–82]. These studies all used relatively unselected popu-
lations,making identificationof the startingmaterial difficult and
contamination of residual -cells a possible explanation of the
observed results. Yet clear demonstration of the -cell differen-
tiation of human duct cells has been provided on purified popu-
lations expressing CA19–9 antigen [83]. Although these cells are
numerous in the pancreas and are easily purified, they lack sus-
tained proliferation and tend to lose their phenotype in vitro [84,
85]. New techniques are thus needed to derive proliferating cells
from the ducts that are able to differentiate into islet cells.
(3) Acinar Cells. Controversy exists concerning the in vivo po-
tential for rodent acinar cells to differentiate into -cells after
injury [86, 87] since a report showing no acinar-to- cell repro-
gramming after 70% pancreatectomy, PDL, or caerulein-induced
pancreatitis [88]. A recent study shed new light on the potential
of exocrine cells by showing their reprogramming into -cells
after injection of viral vectors carrying Pdx1, Ngn3, and MafA
transcription factors into themouse pancreas [89]. The differen-
tiated products had many characteristics of bona fide -cells
with regard to expression profile and insulin content and could
partially reverse the diabetic state. Although the in vitro expan-
sion of human acinar cells has not yet been successful, these cells
remain an attractive source for -cell engineering, and their
therapeutic potential will no doubt be fully explored.
(4) -Cells. The potential of -cells recently aroused much
excitement after the unexpected demonstration of their differ-
entiation into -cells. Collombat et al. showed generation of in-
sulin cells and restoration of hyperglycemia in mice after over-
expressing Pax4 in glucagon-expressing cells [90]. In addition,
using a selective diphtheria toxin-mediated apoptosis model,
Thorel et al. confirmed the differentiation potential of mouse
-cells [91]. After a -cell ablation of 99%, 5%–10% of the
-cells had the capacity to reprogram into -cells, which could
then replicate and substantially increase-cell mass, resulting in
improved glycemic control in the mice. However, the combined
ablation of - and -cells prevented the reprogramming [91].
Whether this plasticity might exist in humans is unknown but is
suggested by the observation of insulinglucagon cells in fi-
brotic pancreases [92]. However, such double-stained cells could
be immature cells differentiating during neogenesis. The possi-
bility of such reprogramming is supported by the in vitro demon-
stration of -cell differentiation of an -cell line using the small
molecule BRD-7389 [93].
This new area of research holds potential promise as -cells
are preserved in T1D or T2D patients [92] and could be a source
for -cell mass expansion. Furthermore, -cells could also be
made available for cell therapy as they can probably be gener-
ated in vitro from human ESCs [94]. However, the findings on -
to -cell differentiation still need confirmation and generaliza-
tion because in vivo STZ-induced-cell ablation does not seem to
provoke -cell replication nor -cell regeneration in nonhuman
primates [95].
Hepatocytes. The rationale for using hepatocytes arises from
the liver’s common endodermal origin with the pancreas. -Cell
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reprogramming of hepatocytes has been shownusing Pdx1 over-
expression, which led to the lowering of hyperglycemia in dia-
beticmice [96]. These results were confirmed by the same group
[97] and others using Pdx1, NeuroD, and Ngn3 overexpression
[98].
Even though the liver is a massive pool of reprogrammable
cells, the use of hepatocytes ex vivo ismadedifficult by the short-
age of donors, poor in vitro proliferation capacities, and rapid
dedifferentiation of these cells [99]. Use of autologous cells via in
situ reprogramming approaches should be evaluated, as autolo-
gous hepatocyte isolation would require surgical procedures
with high comorbidity and should be considered only if a cure of
diabetes is expected.
Porcine Islets. Pigs represent an unlimited supply of islets for
transplantation, and the purity of islet preparations is usually
higher in pigs than in humans [100]. Proof-of-concept of unmod-
ified adult porcine islet xenotransplantation has been made in
nonhuman primates using immunosuppression [101, 102], mi-
croencapsulation [103], or a subcutaneous macrodevice [104]
without immunosuppression. The team of Elliott reported only
modest changes with transplantation into nonhuman primates
of microencapsulated porcine neonatal pancreatic cell clusters
[105]. Importantly, they also showed no evidence of porcine en-
dogenous retrovirus infection after a similar transplant in a hu-
man subject [106]. Preliminary data from phase I and IIa clinical
trials showed a possible reduction of hypoglycemia unawareness
after neonatal porcine islet xenotransplantation without immu-
nosuppression in T1D patients, whereas daily insulin needs were
only modestly reduced [107]. Although still experimental, por-
cine islet xenotransplantation is a promising area of investiga-
tion, and efforts currently focused on improvement of immuno-
suppressive regimens [100] might help overcome current
limitations. Genetic modification is another way of making pig
islets more suitable for transplantation, and transgenic animals
are being evaluated for their potential to avoid rejection or even
retrovirus infections [108].
Other. Multipotent mesenchymal stromal cells (MSCs) are
easily isolated from many tissue sources, are highly expandable
in vitro, are resistant to cryopreservation, and have the potential
to differentiate into many different lineages [109]. Reversal of
diabetes has been reported with human MSCs that differenti-
ated into insulin cells after transplantation into STZ-diabetic
rats without immunosuppression [110]; however, these data
need confirmation. MSCs seem to be able to enhance results of
experimental islet transplantation, perhaps via paracrine effects,
including the secretion of angiogenic cytokines and antiapop-
totic factors, that can regulate endothelial and epithelial perme-
ability, decrease inflammation, and enhance tissue repair [111,
112]. This is corroborated by reports showing amelioration of
hyperglycemia after intravenous [113, 114] or intracardiac [115]
infusion of MSCs in STZ-diabetic mice.
Following up on their previous work with very small embry-
onic-like stem cells, Ratajczak et al. recently published the isola-
tion of these cells in mouse pancreas and their differentiation
into -cell-like derivatives [116]. Although interesting, these re-
sults need corroboration by other teams and careful analysis of
the in vivo behavior and potential of the cells after transplanta-
tion.
(B)HowCan the ImmuneDestructionof the Transplanted
Cells Be Circumvented?
Encapsulation. Cell transplantation for treating diabetes is chal-
lengedby thehost immune systemvia allo- andautoimmunity. Cur-
rent immunosuppression protocols are still associatedwith numer-
ous side effects thatmitigate the benefits of cell therapy compared
with conventional treatment. One alternativeway of bypassing the
immune system is to encapsulate the cells within a barrier allowing
diffusion of glucose, other nutrients, and insulin but not of larger
molecules, cells, or antibodies. This system has the theoretical ad-
vantage of precluding the need for immunosuppression and allow-
ing the use of various cell types including porcine islets [117] or islet
cells derived from stem/precursor cell sources. It also sequesters
the cells, thus avoiding dissemination of potentially tumorogenic
derivatives of genetically-modified cells.
Encapsulation can be configured using many different poly-
mers, methods, and sizes [118]. Microcapsules have some ad-
vantages such as being small and easily placed into the perito-
neal cavity. Their smaller size (conformal to 1,000m) improves
surface-to-volume ratios and exchange of nutrients and mole-
cules. Macroencapsulation is challenging because of the size of
the devices that must be implanted, as well as the problems of
slownutrient delivery and delayed insulin secretory responses to
stimuli. The first phase I trial with microencapsulated human islets
in two T1D patients without immunosuppression showed a de-
crease in insulin daily needs and detectable C-peptide levels after 1
year of follow-up [119]. A more recent study demonstrated the
safety of the technique in four T1D patients but detected only low
levels of C-peptide secretion and no change in insulin requirements
[120]. Ongoing trials should provide more information about the
feasibility of this technique. Preliminary results from the team of
Calafiore using intraperitoneal injection protocols showed possible
reduction of insulin requirements and improvement of hypoglyce-
mia unawareness and HbA1c levels [117].
The field of encapsulation is still struggling with a wide variety
of issues, such as purity, stability, homogeneity, porosity, and
biocompatibility of the materials [121]. Improvement in the effi-
cacy of islet encapsulation has been obtained by combining a
short-term or low-dose immunosuppression regimen with ef-
fects on survival, function, and capsular overgrowth being de-
scribed [122]. Toso et al. showed a marked decrease of over-
growth of alginatemicrocapsules after portal vein infusion while
using a short-term immunosuppression regimen [123]. Lee et al.
evaluated transplants of rat islets with a combined therapy with
cyclosporin A and PEGylation, a surface modification of islets
using polyethylene glycol (PEG), and observed survival and glu-
cose-responsiveness of the islets up to 100 days post-transplan-
tation [124]. They confirmed the efficiency of PEGylation by
showing survival and function of PEGylated rat islets in three of
seven recipients 100 days post-transplantation [125]. Hypoxia
remains a major concern with encapsulation. The survival and
function of encapsulated islets might be improved after stimula-
tion of local neovascularization. One approach that has been
explored incorporated fibroblastic growth factor-1 into alginate
microcapsules, which were then transplanted into rats [126].
Various approaches to macroencapsulation have emerged;
for example, a planar pouch from TheraCyte is made of polytet-
rafluorethylene with an inner impermeable layer with 0.4-m
pores. This device allowed survival of tissue in allogeneic setting
up to 1 year post-implantation [127, 128]. Recently, mouse islets
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and human fetal islet-like clusters macroencapsulated in the de-
vice were shown to survive and ameliorate diabetes after im-
plantation into diabetic SCID mice, whereas adult human islets
had poor survival in the same device [129].
Immunomodulation. Current aims of immunotherapy are to
prevent the onset of T1D or reverse autoimmunity to preserve
residual -cell function and maintain endogenous insulin pro-
duction. Reports have shown some preservation of insulin
secretion in new-onset diabetes using vaccination with glu-
tamic acid decarboxylase or anti-CD3 antibodies [130], for
periods extending up to 5 years post-treatment. However,
two phase III clinical trials using anti-CD3monoclonal antibod-
ies (teplizumab [131] and otelixizumab [132]) failed to meet
their primary endpoints. Other antibodies, such as anti-CD20
rituximab, or antigen-specific agents, such as GAD65 and Dia-
Pep277, are currently being tested [130]. Whether beneficial
Figure 1. Requirements and remaining uncertainties concerning cell therapy for diabetes. Candidate cells for -cell replacement therapy
should be expandable in vitro as required for clinical application, with preservation of their plasticity and without generation of genetic
anomalies (I). The cells might be usable when fresh or after cryostorage. Quality control after storage should allow selection of batches
without phenotypic alteration. A reliable -cell differentiation protocol should then generate glucose-responsive insulin-secreting cells in
large amounts with no undifferentiated remaining cells (II). Whether current protocols would benefit from 3D cell organization or inclusion of
extracellular matrices needs evaluation. Some partially differentiated phenotypes could be tolerated at this point, whereas generation of
genetic anomalies by the differentiation protocol must be excluded. Proof-of-concept and safety assurance should be provided in small and
probably large animal models before cells can be considered for clinical use. Differentiated products should ideally also be storable for future
use. Cell sources allowing large tissue supply (e.g., porcine islets) might be immediately available for patients, but storage with cryostorage or
long-term culture might be warranted to facilitate clinical application (Ia). Uncertainties remain concerning the preparation of the diabetic
patientwith regard to the infusion site or immunosuppressive regimen. Investigations are stillmandatory to determine the ideal injection site,
the immunoprotective protocol (immunobarrier device immunosuppression), and the amount of tissue needed (III). Besides the control of
diabetes andmonitoring of treatment side effects, clinical follow-up will be required to determine whether the patient is tolerating the graft,
whether repeated injections are needed, or whether the graft contains cells with tumorogenic potential (IV). Desired, undesired, and
unknown features are represented, respectively, by (), (), and (?). Abbreviation: 3D, three-dimensional.
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effects on autoimmunity can be obtained with similar proce-
dures in patients with long-standing T1D is unknown, and near
total -cell depletion will likely require interventions to en-
hance -cell regeneration.
Classical immunosuppression regimens are still associated
with lifelong side effects that represent an unwanted additional
burden for unstable diabetic patients [133]. This is further com-
plicated by the fact that routinely used calcineurin inhibitors are
toxic for both kidneys and -cells. Cell-specific immunomodula-
tion, regulatory T-cells, or plasmapheresis might prove useful as
alternative or adjuvant therapies. For instance, the anti-T-cell
antibody alemtuzumab has recently been suggested to be im-
portant for achieving a 50% insulin independence at 5 years post-
islet transplantationwhen associatedwith tacrolimus andmyco-
phenolate mofetil [133]. Posselt et al. showed the possibility to
obtain insulin independence 515 days after a single islet trans-
plant with a diabetogenic and nephrotoxic drug-free protocol
including costimulation blockade with belatacept, coupled with
sirolimus, mycophenolatemofetil, and thymoglobulin [134]. On-
going clinical trials will help determine efficacy and safety of
these new treatment combinations.
Because of their immunotolerigenic properties, MSCs have
been regarded as a potential tool to modulate autoimmunity in
T1D [135]. In the NOD mouse model, serial congenic MSCs infu-
sions decreased hyperglycemia after recent onset of diabetes,
which was associated withmodulation of diabetogenic cytokine,
effector T-cell, and antigen-presenting cell profiles [136]. An-
other potential mechanism might be the induction of IL10-se-
creting regulatory T-cells by the infused MSCs [137]. With these
properties and their potential availability in large numbers for
autologous procedures, MSCs may provide benefits in various
ways for diabetes.
With the aim of developing a radical approach to wipe out
autoimmunity against -cells, Voltarelli and coworkers designed
a nonmyeloablative autologous stem cell transplantation proto-
col [138]. Among 23 T1D patients included in the study, 12 were
insulin-independent for a mean of 31months and 8 were receiv-
ing a low-dose insulin regimen (0.1–0.3 IU/kg) for up to 58
months. However, the burden of the procedure and the worri-
some reported side effects (bilateral pneumonia, endocrine dys-
function, and oligospermia) can be expected to limit the clinical
applicability of this approach.
Finally, encapsulation and/or immunomodulation will be
mandatory either in auto- or heterologous transplantation pro-
tocols, with the aim of alleviating the assaults of auto- and allo-
immunity.With recent developments in tissue-engineering tech-
niques, the possibility of deriving -cells from a patient’s tissue
without invasive surgery may become real and would offer the
advantage of repeated procedures in the case of graft failure.
(C) Where to Transplant?
The optimal site for transplantation has not been determined.
Islets were first transplanted into the peritoneal cavity [139].
When injected into the peritoneal cavity, encapsulated synge-
neic and allogenic islets reversed diabetes in Balb/c and NOD
mice for up to 350days after transplantation [140]. However, the
peritoneum does not allow easy access to the grafts as islets can
disperse throughout the cavity or form a sediment on the pelvic
floor. Portal vein injection, which has been used for the initial
clinical trials, is associated with the risk of portal hypertension
and portal vein thrombosis and has been suggested to activate
the innate immune system and instant blood-mediated inflam-
matory reaction [141] that probably contributes to some degree
of cell death. The kidney subcapsular space provides an alterna-
tive microenvironment and allows relatively easy graft retrieval.
However, one study concluded that porcine islet xenotransplan-
tation in this site in primates had poor graft survival [142].
The omental pouch, which is accessible and potentially re-
constructed, appears to provide good blood supply. Survival of
microencapsulated syngeneic islets in the omental pouch has
been shown up to 400 days post-transplantation in NOD mice
[143]. Furthermore, a report concluded that transplanted islets
functionedbetter in the omentum thanunder the kidney capsule
[144]. The gastric submucosal space is another potential site be-
cause it provides good oxygenization of the grafts because of its
vascularization [145] and is accessible via endoscopy for trans-
plantation and subsequent biopsy.
The subcutaneous site, although easy to access, is associated
withmechanical strain, is thought to be immunologically hostile,
and has poor vascularization; however, this might be amelio-
rated by prevascularization techniques [146]. Even the pancreas,
the natural home of islets, holds some theoretical attractions
[147], but there are major concerns about the risk of pancreati-
tis.
(D) Requirements for Translational Studies
Before new sources of cells can be considered for therapy, they
must fulfill some prerequisites (Fig. 1). In vitro, these include
being sufficient in number to provide a clinically relevant mass,
cryoresistant to allow good manufacturing practice-compliant
cell banking, and genetically stable with no signs of genomic al-
teration after expansion [148]. Besides being able to engraft,
survive, and function long-term, transplanted cells must have
minimal neoplastic potential. Cell localization at the time of in-
fusion can be followed by tracing cells with a radioactive label,
as was recently shown during infusion of MSCs in cirrhotic
patients [149]. This technique may be useful for in vivo pro-
cedures in preclinical studies to obtain reassurance about the
noninvasiveness of the transplanted cells [150]. A detailed
checklist of desirable features will be helpful to evaluate
whether a cell type can be an adequate candidate for -cell re-
placement therapy [151].
CONCLUSION
For T1D, -cell replacement therapy is a two-pronged problem
that requires (a) replacing the -cells and (b) controlling the au-
toimmunity and allorejection. There is reason to be optimistic
that sufficient numbers of -cells for transplantation will some-
day be available. Therapy with cells derived from stem cells has
gained attentionwith high levels of differentiation obtainedwith
ESCs and iPSCs. However, safety is a critical issue with these cell
types andmight delay their clinical applications. New insights on
progenitor or somatic cell differentiation have opened the door
for investigation, but in vitro evaluation is necessary to under-
stand their potential for therapy. Stimulating replication or neo-
formation of -cells within the pancreas could be a less invasive
procedure and of high clinical value. New compounds being
tested may be helpful in increasing -cell mass. Progress is also
beingmadewith parallel developments of new immunosuppres-
sive regimens, the quest to induce tolerance, and new ap-
proaches to encapsulation.
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